Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an

Roots Analysis has announced the addition of "Human Microbiome Market, 2019-2030" report to its list of offerings.
 
BON AQUA, Tenn. - Oct. 30, 2020 - PRLog -- The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

Key Market Insights

260 therapy candidates are currently in different phases of development

Nearly 25% of pipeline drugs are in the clinical phase of development, while the rest are in the preclinical / discovery stage. Interestingly, most of these drugs target digestive and gastrointestinal disorders (20%); this is followed by product candidates intended for treatment of oncological disorders (17%) and infectious diseases (13%).

Over 30 microbiome diagnostic tests are currently available / under development

Around 30% of the abovementioned tests have been commercialized, while the rest are under development. Of the total tests, notable examples of companies that launched a microbiome-based diagnostic solution include (in alphabetical order) ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, Luxia Scientific and Varinos.

The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

§  Type of Therapy (Tx)

§  Prescription Drug

§  Prebiotics

§  Probiotics

§  Therapeutic Area (Tx+Dx)

§  Autoimmune Disorders

§  Dental Disorders

§  Digestive and Gastrointestinal Disorders

§  Dermatological Disorders

§  Infectious Disease

§  Metabolic Disorders

§  Oncology

§  Others

§  Key Geographical Regions (Tx+Dx)

§  North America

§  Europe

§  Asia-Pacific and Rest of the World

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Antibody Drug Conjugates Market (5th Edition), 2019-2030 (https://www.rootsanalysis.com/reports/view_document/antib...)

2.      Gene Therapy Market (3rd Edition), 2019 - 2030 (https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html)

3.      Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

4.      Synthetic Lethality-based Drugs and Targets Market, 2019-2030

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Contact
Roots Analysis
***@gmail.com
End
Email:***@gmail.com
Tags:Research
Industry:Reports
Location:Bon Aqua - Tennessee - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Roots Analysis News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share